148 related articles for article (PubMed ID: 35752772)
1. A critical assessment framework to identify, quantify and interpret the sources of uncertainty in cost-effectiveness analyses.
Merész G; Dóczy V; Hölgyesi Á; Németh G
BMC Health Serv Res; 2022 Jun; 22(1):822. PubMed ID: 35752772
[TBL] [Abstract][Full Text] [Related]
2. Development, testing, and implementation of a new procedure to assess the clinical added benefit of pharmaceuticals.
Dóczy V; Wernerné Sódar B; Hölgyesi Á; Merész G; Gaál P
Int J Technol Assess Health Care; 2022 Jul; 38(1):e58. PubMed ID: 35819299
[TBL] [Abstract][Full Text] [Related]
3. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
4. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.
Hagiwara Y; Shiroiwa T
Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648
[TBL] [Abstract][Full Text] [Related]
5. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
[TBL] [Abstract][Full Text] [Related]
6. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
7. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.
Inotai A; Pékli M; Jóna G; Nagy O; Remák E; Kaló Z
BMC Health Serv Res; 2012 Sep; 12():332. PubMed ID: 22999574
[TBL] [Abstract][Full Text] [Related]
8. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
[TBL] [Abstract][Full Text] [Related]
9. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
McCullagh L; Schmitz S; Barry M; Walsh C
Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
[TBL] [Abstract][Full Text] [Related]
10. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
11. Severity-Adjusted Probability of Being Cost Effective.
Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
[TBL] [Abstract][Full Text] [Related]
12. Surgical treatments for women with stress urinary incontinence: the ESTER systematic review and economic evaluation.
Brazzelli M; Javanbakht M; Imamura M; Hudson J; Moloney E; Becker F; Wallace S; Omar MI; Shimonovich M; MacLennan G; Ternent L; Vale L; Montgomery I; Mackie P; Saraswat L; Monga A; Craig D
Health Technol Assess; 2019 Mar; 23(14):1-306. PubMed ID: 30929658
[TBL] [Abstract][Full Text] [Related]
13. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.
Ghabri S; Hamers FF; Josselin JM
Pharmacoeconomics; 2016 Jun; 34(6):617-24. PubMed ID: 26829942
[TBL] [Abstract][Full Text] [Related]
16. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
17. Multivariable and Structural Uncertainty Analyses for Cost-Effectiveness Estimates: Back to the Future.
Mauskopf J
Value Health; 2019 May; 22(5):570-574. PubMed ID: 31104736
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
